

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 April 2025 (24.04.2025)



(10) International Publication Number
WO 2025/083196 A1

(51) International Patent Classification:

C12N 5/078 (2010.01) A61K 40/00 (2025.01)
C12N 5/10 (2006.01) C12M 3/00 (2006.01)

(21) International Application Number:

PCT/EP2024/079474

(22) International Filing Date:

18 October 2024 (18.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23204394.3 18 October 2023 (18.10.2023) EP
23206668.8 30 October 2023 (30.10.2023) EP

(71) Applicant: **TQ THERAPEUTICS GMBH** [DE/DE]; c/o
Christian Eckert, Hermine-von-Parish-Str. 96, 81245 Mu-
nich (DE).

(72) Inventors: **RADISCH, Sabine**; c/o TQ Therapeutics
GmbH, c/o Christian Eckert, Hermine-von-Parish-Str. 96,
81245 Munich (DE). **ECKERT, Christian**; c/o TQ Thera-
peutics GmbH, c/o Christian Eckert, Hermine-von-Parish-
Str. 96, 81245 Munich (DE).

(74) Agent: **SCHIWECK, Wolfram** et al.; c/o Schiweck
Weinzierl Koch Patentanwälte, Ganghoferstrasse 68b,
80339 Munich (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: A METHOD OF MANUFACTURING A CELLULAR THERAPY PRODUCT AND RESPECTIVE KITS AND DEVICES

(57) Abstract: The present invention relates to a method of manufacturing a cellular therapy product, wherein the cellular therapy product comprises a first cellular surface receptor which is able to bind to a drug target molecule (on the surface) of a drug target cell and/or wherein the cellular therapy product produces and/or secretes a polypeptide which is able to bind to a drug target molecule either soluble or associated with a drug target cell. This method comprises a) enriching via reversible immobilization (in a holding step) a cellular therapy starting cell obtained from a sample comprising the cellular therapy starting cell, using at least one second cellular surface receptor of the cellular therapy starting cell, and b) genetically modifying the cellular therapy starting cell using one or more reagent(s) comprising a gene construct for expression of the first cellular surface receptor and/or for expression and/or secretion of the polypeptide, thereby generating a precursor of the cellular therapy product, wherein the method takes place in a closed system.

WO 2025/083196 A1